SKP 1032

Drug Profile

SKP 1032

Alternative Names: SKP-1032

Latest Information Update: 18 Jan 2011

Price : $50

At a glance

  • Originator SkyePharma AG
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Inflammation; Pain

Highest Development Phases

  • No development reported Inflammation; Pain

Most Recent Events

  • 18 Jan 2011 No development reported - Phase-I for Pain in United Kingdom (PO)
  • 18 Jan 2011 No development reported - Phase-I for Inflammation in United Kingdom (PO)
  • 29 Jun 2007 SKP 1032 is available for licensing (http:www.skyepharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top